Targeted elimination of activated hepatic stellate cells by an anti‐epidermal growth factor‐receptor single chain fragment variable antibody‐tumor necrosis factor‐related apoptosis‐inducing ligand (scFv425‐sTRAIL)

ConclusionsEvidence is presented for the successful application of the scFv425‐sTRAIL fusion protein in the targeted elimination of activated hepatic stellate cells via EGFR and simultaneous activation of the caspase pathway. scFv425‐sTRAIL may thus represent a new therapeutic compound against liver fibrosis. Copyright © 2014 John Wiley & Sons, Ltd.
Source: The Journal of Gene Medicine - Category: Genetics & Stem Cells Authors: Tags: Research Article Source Type: research